Novavax Announces Pricing of $65 Million Public Offering of Co... - 16 December 2022 17:23

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire-AsiaNet/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of ...

  Novavax Announces Pricing of $150 Million Offering of Converti... - 16 December 2022 16:56

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire-Asianet/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of it...

  Novavax Announces Proposed Offering of $125 Million of Convert... - 16 December 2022 02:00

GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire-AsiaNet/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertib...

  Pharming announces positive interim analysis data from open-la... - 15 December 2022 17:00

LEIDEN, Netherlands, Dec. 15, 2022 /PRNewswire-AsiaNet/ -- V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated t...

  Hovione and GEA announce a strategic collaboration to advance ... - 15 December 2022 00:58

LISBON, Portugal, Dec. 14, 2022, /PRNewswire-AsiaNet/ -- Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s dev...

  Circulating Tumor Cell detection by Menarini Group's CELLSEARC... - 15 December 2022 00:00

Huntingdon Valley, PA, December 13, 2022, /PRNewswire-AsiaNet/-- Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems' CELLSEARCH(R) System and the CELLSERCH(R) Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor...

  Japanese Healthcare Startup Ubie, Inc. Closes Extended Series ... - 08 December 2022 19:00

TOKYO, Dec. 8, 2022 /Kyodo JBN-AsiaNet/ -- Ubie, Inc., a Tokyo-based healthcare startup, announced on December 8 that it has closed its Series C round at $45 million by raising $19 million in an extension round. The new funding will enable Ubie to accelerate its growth and strengthen its p...

  Lost childhood: a 'tight-knit' network to combat abuse and dis... - 07 December 2022 23:29

ROME, Dec. 7, 2022 /PRNewswire-AsiaNet/ -- On Radar takes off, the first meeting of the Think Tank of Fondazione Internazionale Menarini Setting real changes in motion through dialogue among experts in order to tackle the unresolved issues of juvenile distress. This was the topic addre...

  Pharming announces publication of data from Phase 3 Study of l... - 07 December 2022 17:00

LEIDEN, Netherlands, Dec. 7, 2022 /PRNewswire-AsiaNet/-- Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency The peer-reviewed publication heightens international...

  PGTG successfully develops SGF bone-derived factor to restore ... - 07 December 2022 16:23

BEIJING, Dec. 7, 2022 /PRNewswire-AsiaNet/ -- The bone-derived skeletal growth factor (SGF), jointly developed by a research facility under the direction of leading biochemist, academician and researcher Zhao Yufen and the Anhui-based research center of one of the world's health industry lead...